Threadgill Financial LLC Buys New Stake in Novo Nordisk A/S (NYSE:NVO)

Threadgill Financial LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 44,339 shares of the company's stock, valued at approximately $3,079,000. Novo Nordisk A/S makes up approximately 1.7% of Threadgill Financial LLC's investment portfolio, making the stock its 18th biggest position.

Several other institutional investors also recently modified their holdings of NVO. Victory Capital Management Inc. lifted its position in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after acquiring an additional 30,420 shares during the period. Clear Creek Financial Management LLC purchased a new position in Novo Nordisk A/S in the fourth quarter worth about $450,000. DSM Capital Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 16.7% in the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock worth $172,678,000 after buying an additional 286,912 shares during the last quarter. Finally, Channing Global Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $354,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 1.8%

NYSE NVO traded up $1.31 on Wednesday, hitting $72.22. The stock had a trading volume of 6,912,350 shares, compared to its average volume of 6,858,394. The business's fifty day moving average price is $65.62 and its 200 day moving average price is $81.15. The stock has a market cap of $324.09 billion, a price-to-earnings ratio of 21.95, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVO shares. BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.